WRALtechwire.com logo

United Therapeutics jumps on takeover talk; GSK a potential bidder

United Therapeutics

Aug, 4 2017, 8:27 AM

United Therapeutics, which has a major operation in RTP, could be a takeover for three pharmaceutical giants, including GlaxoSmithKline.

United Therapeutics stock surged on Wall Street early Friday, climbing some 10 percent.

The London Evening Standard reports that United Therapeutics could be worth as much as $200 a share, or some $8.7 billion.

Its market cap as of Friday is around $5.5 billion based on current stock prices.

GSK, which also is a big player in RTP, is said by sources to be interested.

Others include Novartis and Giliead, the newspaper reported.

GSK is led by new CEO Emma Walmsley who has said she is open to making acquisitions.

United Therapeutics provides treatments for pulmonary arterial hypertension (PAH).

As the Evening Standard reported, United and GSK have a history.

"The company was founded and run by Martine Rothblatt, a transgender entrepreneur who quit her satellite radio businessSirius XM to start United in 1996 in an effort to save her daughter, a PAH sufferer. She bought Glaxo’s PAH treatment, which it had deemed commercially unviable," the newspaper noted.

​GSK and United Therapeutics declined to comment on the report.

Read more at: